Cl.C(N=[C:5]1[N:14]([CH2:15][C:16]#[N:17])[CH2:13][C:12]2[C:7](=[CH:8][CH:9]=[C:10]([Cl:19])[C:11]=2[Cl:18])[NH:6]1)#N.C(=O)([O-])[O-:21].[K+].[K+]>C(O)CO>[Cl:18][C:11]1[C:10]([Cl:19])=[CH:9][CH:8]=[C:7]2[C:12]=1[CH2:13][N:14]1[CH2:15][C:16](=[O:21])[NH:17][C:5]1=[N:6]2To a solution of 10 ml of ethylene glycol in 0.5 ml (0.005 moles) of cc. hydrochloric acid, warmed to 120° C., 0.28 g (0.001 mole) of (2-cyanoimino-5,6-dichloro-1,2,3,4-tetrahydroquinazolin-3-yl) acetonitrile are added, and the solution is stirred at the same temperature for 20 minutes. Then it is cooled to room temperature and made neutral with 10% potassium carbonate solution. The separated crystals are filtered off. Thus 0.27 g (96.4%) of crude 6,7-dichloro-1, 5-dihydroimidazo[2,1-b]quinazolin-2[3H]-one base are obtained (m.p.>300° C., HPLC content: 96.3%), which is dissolved in a hot mixture of 7 ml of methanol and 6 ml of cc. ethanolic hydrogen chloride (hydrogen chloride content: 0.76 moles/1000 ml) and allowed to crystallize. Then it is cooled, the separated product is filtered off and washed with a slight amount of ethanol.